N

    NanoViricides Inc (NNVC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $1.25
    +0.02 (+1.21%)

    Market Cap: $31.65M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    78%(18/23)
    Avg Surprise
    +4.71%

    Upcoming Estimates

    Jun 30, 2026
    EPS Consensus$-0.06
    Range$-0.06 - $-0.06
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Sep 30, 2026
    EPS Consensus$-0.09
    Range$-0.09 - $-0.09
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.10-11.1%
    60d ago$-0.10-11.1%
    30d ago$-0.10-11.1%
    7d ago$-0.10-11.1%
    Current$-0.09
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Sep 26EST
    		-$-0.09---
    Jun 26EST
    		-$-0.06---
    Mar 26
    		$-0.09$-0.08-12.50%Miss+35.7%
    Dec 25
    		$-0.11$-0.08-37.50%Miss+20.9%
    Sep 25
    		$-0.10$-0.18+44.44%Beat+56.1%
    Jun 25
    		$-0.12$-0.20+40.00%Beat+36.8%
    Mar 25
    		$-0.14$-0.19+26.32%Beat+12.5%
    Dec 24
    		$-0.14$-0.18+22.72%Beat+22.7%
    Sep 24
    		$-0.23$-0.17-34.12%Miss-34.1%
    Jun 24
    		$-0.19$-0.20+5.00%Beat+37.7%
    Mar 24
    		$-0.16$-0.19+15.79%Beat-6.7%
    Dec 23
    		$-0.18$-0.19+5.26%Beat-20.0%
    Sep 23
    		$-0.17$-0.17+0.00%Beat-21.4%
    Jun 23
    		$-0.31$-0.17-79.53%Miss-103.5%
    Mar 23
    		$-0.15$-0.17+11.76%Beat+6.3%
    Dec 22
    		$-0.15$-0.16+6.25%Beat+11.8%
    Sep 22
    		$-0.14$-0.17+17.65%Beat+39.1%
    Jun 22
    		$-0.15$-0.15+0.00%Beat+16.7%
    Mar 22
    		$-0.16$-0.22+27.27%Beat+15.8%
    Dec 21
    		$-0.17$-0.22+22.73%Beat+22.7%
    Sep 21
    		$-0.23$-0.20-15.00%Miss-4.5%
    Jun 21
    		$-0.18$0.00N/ABeat+21.7%
    Mar 21
    		$-0.19$0.00N/ABeat+84.7%
    Dec 20
    		$-0.22$0.00N/ABeat+56.0%
    Sep 20
    		$-0.22N/AN/ABeat+46.3%
    Jun 20
    		$-0.23N/AN/ABeat+61.7%
    Mar 20
    		$-1.24N/AN/ABeat-106.7%
    Dec 19
    		$-0.50$-0.60+16.67%Beat+16.7%
    Sep 19
    		$-0.41N/AN/ABeat+31.7%
    Jun 19
    		$-0.60$-0.80+25.00%Beat-2900.0%
    Mar 19
    		$-0.60$-0.60+0.00%Beat-1900.0%
    Dec 18
    		$-0.60$-0.60+0.00%Beat-1400.0%
    Sep 18
    		$-0.60N/AN/ABeat-1900.0%
    Jun 18
    		$-0.02N/AN/ABeat+50.0%
    Mar 18
    		$-0.03N/AN/ABeat+40.0%
    Dec 17
    		$-0.04N/AN/ABeat+92.5%
    Sep 17
    		$-0.03N/AN/ABeat+97.1%
    Jun 17
    		$-0.04N/AN/ABeat-
    Mar 17
    		$-0.05N/AN/ABeat-
    Dec 16
    		$-0.53N/AN/ABeat-
    Sep 16
    		$-1.05N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-2.99EV/EBITDA-1.11x
    Price/FCF-3.68xFCF Yield-27.18%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-90.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio3.17xQuick Ratio3.17x
    Trading Statistics
    Beta1.69Avg Volume285.15K
    52-Week High$2.2352-Week Low$0.85

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.29
    SMA 20$1.35
    SMA 50$1.45
    SMA 200$1.27
    EMA 10$1.29
    EMA 20$1.35
    EMA 50$1.41
    EMA 200$1.36

    MACD

    Line: -0.06Signal: -0.06Hist: -0.01

    ADX

    ADX: 22.3+DI: 15.4-DI: 22.8

    Aroon & PSAR

    Aroon Up20.0
    Aroon Down96.0
    PSAR$1.22

    Bollinger Bands

    Upper Band$1.48
    Lower Band$1.21
    %B Position2040%(Upper)
    Band Width0.16

    RSI (14-Day)

    Neutral
    35.4

    Momentum Oscillators

    Stoch %K11.4
    Stoch %D9.7
    Williams %R-83.3
    ROC (10d)-7.7%
    Momentum-0.10
    CCI (20d)-103.9
    MFI (14d)47.5

    Volatility Measures

    ATR (14d)$0.08(6.6%)
    StdDev (20d)0.07
    Hist Vol33.1%(Moderate)

    Volume Flow

    VWAP$1.27
    OBV35.1M
    AD Line-870.7K
    CMF (20d)-0.391

    Volume Metrics

    Avg Vol (20d)273.9K
    Vol Ratio1.4x
    VWMA (20d)$1.35

    Pivot Points

    R3$1.33
    R2$1.30
    R1$1.27
    Pivot Point$1.25
    S1$1.21
    S2$1.19
    S3$1.16

    Advanced Oscillators

    TSI-24.84
    Ultimate Osc27.4
    KST-140.83

    Financial Data

    QuarterMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$0$0$0$161,126$0$0$0$190,603$0$0$0N/A
    Gross Profit$0$0$0$-161,126$0$0$0$-190,603$0$0$0N/A
    Operating Expenses$2.03M$2.23M$1.80M$2.12M$2.25M$2.06M$3.17M$2.39M$1.91M$2.18M$2.03M$3.68M
    R&D$1.29M$1.12M$993,066$1.18M$1.28M$1.16M$1.93M$1.18M$1.21M$1.57M$1.47M$2.91M
    SG&A$744,276$1.11M$803,619$938,196$966,905$902,700$1.23M$1.21M$693,742$610,877$564,926$763,422
    Operating Income$-2,030,218$-2,233,174$-1,796,685$-2,115,604$-2,249,156$-2,059,051$-3,167,834$-2,391,361$-1,908,403$-2,184,756$-2,031,591$-3,676,373
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$3.11M$0$0$0$1.90M$0$0$36,493$0
    Income Before Tax$-1,989,333$-2,220,719$-1,785,058$-5,222,692$-2,216,783$-2,027,491$-3,126,811$-4,288,240$-1,854,476$-2,101,622$0$-3,569,993
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-1,989,333$-2,220,719$-1,785,058$-2,095,881$-2,216,783$-2,027,491$-3,126,811$-2,355,987$-1,854,476$-2,114,937$-1,968,746$-3,569,993
    EBITDA$-1,859,699$-2,087,636$-1,652,238$-1,934,755$-2,025,600$-1,831,459$-2,931,198$-2,165,384$-1,664,520$-1,912,291$-1,743,129$-3,381,111
    EBIT$-1,989,333$-2,220,719$-1,785,058$-2,095,881$-2,216,783$-2,027,342$-3,126,811$-2,355,987$-1,854,476$-2,101,622$-1,932,253$-3,569,993
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NNVC

    News

    Nanoviricides | 424B5: Prospectus

    This document is a 424B5 Prospectus filing for Nanoviricides. It is a regulatory filing that contains important financial and operational information about the company, likely related to a new offering or registration.

    Moomoo•8/22/26•
    Neutral

    NanoViricides (NYSE American: NNVC) sets up warrant resale, up to $4.4M cash

    NanoViricides (NNVC) has filed an S-3 registration statement for the resale of up to 2,516,339 common shares associated with outstanding Common Stock Purchase Warrants. While NanoViricides will not directly sell shares in this offering, it could receive up to $4.4 million if all warrants are exercised in cash at $1.75 per share. The company, a clinical-stage antiviral developer with no current revenue, faces an auditor's going concern warning, indicating significant financial and liquidity risk.

    Stock Titan•8/21/26•
    Bearish

    Ebola outbreak has killed 2,325 as oral drug trial nears

    NanoViricides (NNVC) has received regulatory approval in the Democratic Republic of Congo (DRC) for a Phase II clinical trial of its oral gummies treatment, NV-387, for the current Bundibugyo ebolavirus outbreak. The trial is expected to begin soon, with the drug product already in DRC. As of August 14, 2026, the outbreak has resulted in 4,945 confirmed cases and 2,325 deaths in the DRC, with a crude fatality rate of 46%.

    Stock Titan•8/18/26•
    Somewhat-Bullish

    ETFs Investing in NanoViricides, Inc. Stocks

    This article lists ETFs that invest in NanoViricides, Inc. stocks, providing details such as market value, weight, issuer, management style, and expense ratio for each fund. It highlights that these ETFs make investing in stocks more accessible with lower risk. The specific ETF mentioned is the Bridgeway Ultra-Small Company Market ETF (BUSM EA), which holds NanoViricides, Inc. stocks.

    TradingView•8/17/26•
    Neutral

    NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak

    NanoViricides, Inc. has received regulatory approval from ACOREP in the Democratic Republic of Congo (DRC) to begin a Phase II clinical trial for its NV-387 Oral Gummies as a treatment for the current Bundibugyo Ebolavirus outbreak and other Ebola viruses. The company believes its oral, broad-spectrum antiviral drug could be revolutionary in combating the expanding Ebola outbreak in the DRC, which has seen over 4,000 confirmed cases and nearly 1,900 deaths. This trial aims to offer an oral treatment option, which is highly advantageous in resource-limited settings compared to infusion-based therapies.

    ACCESS Newswire•8/13/26•
    Bullish

    Frequently Asked Questions About NNVC

    Does NNVC pay dividends?
    NanoViricides Inc (NNVC) does not currently pay a regular dividend.
    What is NNVC's market cap?
    NanoViricides Inc (NNVC) has a market capitalization of $31.65M with a current stock price of $1.25.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In